Vicarious Surgical Inc. received a nyse delisting notice notice regarding market value (rules 802.01B).
“March 3, 2026, the New York Stock Exchange (the “NYSE”) notified Vicarious Surgical Inc. (the “Company”) that the NYSE had determined to (A) immediately suspend trading in the Company’s common stock, par value $0.0001 per share (the “Common Stock”), due to a determination that the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000 pursuant to Section 802.01B of the NYSE Listed Company Manual, and (B) commence proceedings to delist the Commo”
Listing & Compliance Notices
Vicarious Surgical Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).
“YSE’s determination. Trading in the Company’s Common Stock will be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026, and continued compliance with the NYSE’s other continued listing requirements.”
Listing & Compliance Notices
Vicarious Surgical Inc. received a nyse delisting notice notice regarding other (rules 802.01D).
“December 15, 2025, the NYSE notified the Company that the NYSE has determined to (a) commence proceedings to delist the Company’s warrants, with thirty warrants exercisable for one share of Common Stock, at an exercise price of $345.00 per share, and listed to trade on the NYSE under the symbol “RBOT.WS” (the “Public Warrants”) and (b) immediately suspend trading in the Public Warrants due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company does not intend to appeal the NYSE’s determination. Trading in the Company’s Common Stock w”
Equity Issuances
Vicarious Surgical Inc. issued Series B common warrants (the “Series B Common Warrants”) to purchase an aggregate of 1,150,000 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.
“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”
Equity Issuances
Vicarious Surgical Inc. issued Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 1,150,000 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.
“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”
Equity Issuances
Vicarious Surgical Inc. issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 561,700 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.
“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”
Equity Issuances
Vicarious Surgical Inc. issued 588,300 shares of common stock to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.
“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”
Listing & Compliance Notices
Vicarious Surgical Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).
“April 10, 2025, Vicarious Surgical Inc. (the “Company”) received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating the Company was no longer in compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”) due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. In accordance with applicable NYSE p”
Auditor Changes
Vicarious Surgical Inc. engaged Cherry Bekaert LLP as its auditor.
“On July 7, 2025, in connection with the Company’s dismissal of Deloitte, the Audit Committee approved the engagement of Cherry Bekaert as its new independent registered public accounting firm”
Auditor Changes
Vicarious Surgical Inc. dismissed Deloitte & Touche LLP as its auditor.
“On July 7, 2025, the Company dismissed Deloitte & Touche LLP ("Deloitte") as the Company’s independent registered public accounting firm.”
Randy Clark was appointed as Director at Vicarious Surgical Inc..
“the Company’s Board of Directors (the “Board”) has appointed Mr. Clark to the Board, effective as of April 25, 2025, pending customary conflict checks.”
Randy Clark resigned as President at Vicarious Surgical Inc..
“On March 18, 2025, Randy Clark resigned as President of Vicarious Surgical Inc. (the “Company”), effective as of April 25, 2025.”
Sarah Romano was appointed as Chief Financial Officer and Treasurer at Vicarious Surgical Inc..
“On March 13, 2025, Vicarious Surgical Inc. (the “Company”) announced that Sarah Romano was appointed by the Board of Directors of the Company (the “Board”) as Chief Financial Officer and Treasurer of the Company, effective April 1, 2025”
John Mazzola departed as Chief Operating Officer at Vicarious Surgical Inc..
“On February 12, 2025, John Mazzola notified the Company that he intends to retire from his position as Chief Operating Officer of Vicarious Surgical Inc. (the “Company”), effective April 1, 2025.”
William Kelly departed as Chief Financial Officer at Vicarious Surgical Inc..
“On January 17, 2025, Vicarious Surgical Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with William Kelly in connection with Mr. Kelly’s previously disclosed departure from his role as Chief Financial Officer of the Company.”
Earnings Releases
Vicarious Surgical Inc. reported the quarter ended March 31, 2024 results: net income GAAP net loss for the first quarter was $17.0 million, equating to a net loss per share of $0.10, EPS $0.10. Guidance reaffirmed.
“Vicarious Surgical Reports First Quarter 2024 Financial Results”
Earnings Releases
Vicarious Surgical Inc. reported fourth quarter and full year ended December 31, 2023 results: net income GAAP net loss for the fourth quarter was $13.1 million, equating to a net loss per share of $0.06, as compared to a GAAP, EPS GAAP net loss for the fourth quarter was $13.1 million, equating to a net loss per share of $0.06, as compared to a GAAP. Guidance reaffirmed.
“On March 4, 2024, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023 and providing a business update.”
David Styka resigned as Executive Chairman at Vicarious Surgical Inc..
“On February 27, 2024, David Styka notified the Board of Directors (the “Board”) of Vicarious Surgical Inc. (the “Company”) of his intent to resign as executive chairman and member of the Board, effective February 29, 2024.”
Adam Sachs changed role as President at Vicarious Surgical Inc..
“In connection with the appointment of Mr. Clark, Adam Sachs stepped down from his role as President.”
Randy Clark was appointed as President at Vicarious Surgical Inc..
“On January 29, 2024, Vicarious Surgical Inc. (the “Company”) announced the appointment of Randy Clark as the President of the Company, effective as of the same day”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.